Developed by Russian Defence Ministry and the Gamaleya Research Institute, the vaccine is presently undergoing the last, that is, the third stage of the trial. Sharing details of the same, Grindev said, "The trials are extremely important. We have to understand that the vaccine must be safe."
The clinical trials of the vaccine had began on 18 June with a total of 38 volunteers, all of whom had developed an immunity. The first group of volunteers was successfully discharged on 15 July, and the second group on 20 July.
Grindev also announced that once the vaccine is out, medical professionals and senior citizens will be the first ones to get vaccinated. Grindev shared crucial development while speaking at the opening of a cancer centre building in the city of Ufa.
As you are no doubt aware, Swarajya is, all in all, a reader-subscription-backed business model and in order to make sure we build a media platform with only the best interests of India at heart, we need your backing.
And in challenging times like this, we need your support now more than ever—to continue bringing you stories that are often shrugged off.
For us to invest in quality reporting and continue bringing you the right stories, it takes a lot of time and money.
Partner with us, be a patron or a subscriber. We need your support, throughout.